Literature DB >> 8326218

Type 2 neurofibromatosis: the need for supraregional care?

D G Evans1, R Ramsden, S M Huson, R Harris, R Lye, T T King.   

Abstract

The results of a U.K. study of 145 cases of type 2 neurofibromatosis has shown generally very poor operative results in terms of hearing and facial nerve preservation. Only 9 out of 118 vestibular schwannoma (acoustic neuroma) operations resulted in any clinically detectable hearing preservation and only 32 left the patient with good or normal (House grade I or II) ipsilateral facial nerve function. Although operation is still the definitive treatment of vestibular schwannoma (acoustic neuroma) and may be a lifesaving procedure, it appears that the evidence in favour of early operation is only valid when carried out in highly specialized centres. The special problems of NF2 cases who may go on to develop multiple spinal and cranial tumours making them wheelchair bound and blind as well as deaf warrants a careful experienced approach. Timing of operations may be critical for the enhancement of useful years of quality life. We therefore propose the setting up of a national NF2 register, with the management of cases at a few supraregional centres.

Entities:  

Mesh:

Year:  1993        PMID: 8326218     DOI: 10.1017/s002221510012328x

Source DB:  PubMed          Journal:  J Laryngol Otol        ISSN: 0022-2151            Impact factor:   1.469


  12 in total

1.  Differential diagnosis of type 2 neurofibromatosis: molecular discrimination of NF2 and sporadic vestibular schwannomas.

Authors:  C L Wu; N Thakker; W Neary; G Black; R Lye; R T Ramsden; A P Read; D G Evans
Journal:  J Med Genet       Date:  1998-12       Impact factor: 6.318

Review 2.  Neurofibromatosis type 2.

Authors:  D G Evans; M Sainio; M E Baser
Journal:  J Med Genet       Date:  2000-12       Impact factor: 6.318

Review 3.  [Neurofibromatoses].

Authors:  A Zimmer
Journal:  Radiologe       Date:  2013-12       Impact factor: 0.635

4.  Paediatric presentation of type 2 neurofibromatosis.

Authors:  D G Evans; J M Birch; R T Ramsden
Journal:  Arch Dis Child       Date:  1999-12       Impact factor: 3.791

5.  Probability of bilateral disease in people presenting with a unilateral vestibular schwannoma.

Authors:  D G Evans; R Lye; W Neary; G Black; T Strachan; A Wallace; R T Ramsden
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-06       Impact factor: 10.154

6.  Molecular genetic analysis of the NF2 gene in young patients with unilateral vestibular schwannomas.

Authors:  A Mohyuddin; W J Neary; A Wallace; C L Wu; S Purcell; H Reid; R T Ramsden; A Read; G Black; D G R Evans
Journal:  J Med Genet       Date:  2002-05       Impact factor: 6.318

7.  Predictors of the risk of mortality in neurofibromatosis 2.

Authors:  Michael E Baser; J M Friedman; Dana Aeschliman; Harry Joe; Andrew J Wallace; Richard T Ramsden; D Gareth R Evans
Journal:  Am J Hum Genet       Date:  2002-08-22       Impact factor: 11.025

8.  Clinical outcome of neurofibromatosis type 2-related vestibular schwannoma: treatment strategies and challenges.

Authors:  Byung Sup Kim; Ho Jun Seol; Jung-Il Lee; Hyung Jin Shin; Kwan Park; Doo-Sik Kong; Do-Hyun Nam; Yang-Sun Cho
Journal:  Neurosurg Rev       Date:  2016-05-04       Impact factor: 3.042

9.  Genotype/phenotype correlations in type 2 neurofibromatosis (NF2): evidence for more severe disease associated with truncating mutations.

Authors:  D G Evans; L Trueman; A Wallace; S Collins; T Strachan
Journal:  J Med Genet       Date:  1998-06       Impact factor: 6.318

Review 10.  Neurofibromatosis type 2 (NF2): a clinical and molecular review.

Authors:  D Gareth R Evans
Journal:  Orphanet J Rare Dis       Date:  2009-06-19       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.